Sign inJoin waitlistJoin the waitlist

John Strickler

Adjunct Professor in the Department of Medicine · Duke Department of Medicine

Credentials: · · ·

History

Duke Department of Medicine
Present
Duke Cancer Institute
Present

Duke University, School of Medicine
2008–2011
University of Washington
2005–2008
The University of Chicago
2005

Research

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
New England Journal of Medicine · 2020 · 1,421 citations
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Systematic review or meta-analysis · Journal of Clinical Oncology · 2023 · 549 citations
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
New England Journal of Medicine · 2023 · First of 22 authors · 440 citations

Hope Uronis
21 papers
Tanios Bekaii-Saab
20 papers
HH
Herbert Hurwitz
12 papers
Michael Morse
11 papers
Shiao-Wen Hsu
11 papers
Peter Allen
10 papers · 5 as a resident
David Hong
8 papers
JJ
Jingquan Jia
8 papers
Michael Datto
8 papers
Michael Lidsky
8 papers
Syed Zafar
8 papers
Christina Wu
7 papers

Grants

The Duke University - Duke Cancer Institute National Clinical Trials Network LAPS (UG1) Support Grant
National Cancer Institute · UG1
PI · $634.4K · Duke University
2026–2032
Cancer Center Support Grant (CCSG)
National Cancer Institute · P30
Project lead · $290.3K · Duke University
1997–2029

Clinical trials

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Principal investigator · Withdrawn · Phase 2
Academic and Community Cancer Research United
2023–2024
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Principal investigator · Unknown · Phase 2
Academic and Community Cancer Research United
2020–2024
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Principal investigator · Terminated
Academic and Community Cancer Research United
2020–2023
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2019–2021